Instructions for Gaviscon (Sodium alginate, bicarbonate, calcium carbonate) mint
English product name
Gaviscon
Release form
susp. d/ingestion (mint) 500 mg+267 mg+160 mg/10 ml: fl 150 ml or 300 ml
Suspension description Gaviscon:
The infusion suspension (mint) is viscous, opaque, from almost white to creamy, with a mint smell.
10ml
alginate sodium 500 mg
sodium hydrogen carbonate 267 mg
calcium carbonate 160 mg
Auxiliary substances:
carbomer - 65 mg,
methylparahydroxybenzoate - 40 mg,
propyl parahydroxybenzoate - 6 mg,
sodium saccharinate - 10 mg,
peppermint oil - 1 mg,
sodium hydroxide - 26.667 mg,
water purified - up to 10 ml.
150 ml - bottles of dark glass with the control of the first opening.
300 ml - bottles of dark glass with the control of the first opening.
Form of release pills Gaviscon:
tab. chewing (mint) 250 mg+133.5 mg+80 mg: 12, 24 or 48 units
Pharmacotherapy group
Pill Description:
Tablets chewing (mint) from almost white to cream color with small impurities, round, flat, with beveled edges; on one side of the tablet - a picture of a circle and a sword, on the other - "G 250"; with a mint smell.
1 tab.
alginate sodium 250 mg
sodium hydrogen carbonate 133.5 mg
calcium carbonate 80 mg
Auxiliary substances:
mannitol - 255 mg,
macrogol 20 000 - 30 mg,
magnesium stearate - 4 mg,
aspartame - 3.75 mg,
copovidone - 28 mg,
potassium acetulpham - 3.75 mg,
mint flavor - 12 mg.
A02BX Other anti-ulcer drugs Gaviscon
Antacid preparation
Active substance
sodium hydrogen carbonate
alginate sodium
Reflux esophagitis treatment
The shelf life is two years. Do not apply after the expiry date indicated on the package.
Testimony Gaviscon:
- treatment of symptoms such as acid bursting,
- heartburn,
- dyspepsia (digestive disturbance,
- feeling of heaviness in the stomach) arising after eating,
- in patients with gastroesophageal reflux or during pregnancy.
Method of use, course and dosage:
The drug Gaviscon is taken inside. The tablet should be thoroughly chewed.
Adults and children over 12 years of age are given two to four tabas each after meals and before bed (up to 4 times per day).
If symptoms persist after seven days of use, the patient should see a doctor to review the treatment.
Elderly patients do not need a dose correction.
Patients with liver dysfunction do not need a dose change.
Patients with kidney failure should take the drug Gaviscon with care if they follow a low salt diet.
Syrup application, course and dosage:
The drug Gaviscon is used internally.
Adults and children over twelve years old are given 10-20 ml of suspensions after eating and before going to bed. The maximum daily dose is 80 ml.
Children aged six to twelve years are given 5-10 ml each after eating and before bed. The maximum daily dose is 40 ml.
Pharmacological effect:
After ingestion, the active substances of the drug Gaviscon quickly interact with the acidic content of the stomach. This forms an alginate gel with a pH value close to neutral. The gel forms a protective sheath on the surface of the stomach contents, preventing the appearance of gastroesophageal reflux for up to 4 hours.
In severe cases (with regurgitation), the gel enters the esophagus faster than the rest of the gastric contents, where it reduces mucous membrane irritation.
The reduction of irritation is felt 3-4 minutes after the drug Gaviscon is taken.
Use in liver disorders
Patients with liver dysfunction do not need dose correction.
Terms of Sale
The drug is released without a prescription.
Application in elderly patients
No dose correction is required for elderly patients.
Use in children
The use of the preparation in children under 12 years of age is contraindicated.
- Nosology (ICD codes)
- K21
- Gastroesophageal reflux
- K30
- Functional dyspepsia (digestive disorder)
- O99.6
- Digestive diseases complicating pregnancy, childbirth and the postpartum period
- R12
- Izzhoga
